Kane Biotech Issued New Patent in Japan for DispersinB®

October 13, 2012

Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce the issuance of Patent (No.5073169) entitled “Compositions and Methods for Enzymatic Detachment of Bacterial and Fungal Biofilms” by the Japan patent office. This patent covers the Company’s unique DispersinB® biofilm technology.

The patent claims the gene encoding DispersinB® enzyme and also amino acid sequence of the enzyme. In addition, the claims include: (i) a method of producing DispersinB, (ii) pharmaceutical compositions comprising DispersinB® and an antibody or an antibiotic/ antimicrobial, (iii) methods of administration, and (iv) applications in medical devices, wound care and oral care.

The issuance of this new DispersinB patent in Japan follows the recent issuance of the Japanese patent for the Company’s Aledex® antibiofilm-antimicrobial technology for medical device coatings which was announced in September this year.

“We are very excited to have been granted this Japanese patent that provides additional global protection for DispersinB technology.” stated Gord Froehlich, President and Chief Executive Officer of Kane Biotech.
 

Share This Story

Back

We are very excited to have been granted this Japanese patent that provides additional global protection for DispersinB technology.” stated Gord Froehlich, President and Chief Executive Officer of Kane Biotech.